soliciting comments on any public
interest issues raised by the complaint
or complainant’s filing pursuant to the
Commission’s Rules of Practice and
Procedure.

FOR FURTHER INFORMATION CONTACT: Lisa
R. Barton, Secretary to the Commission,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone (202) 205–2000. The
public version of the complaint can be
accessed on the Commission’s
Electronic Document Information
System (EDIS) at https://edis.usitc.gov,
and will be available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)

General information concerning the
Commission may also be obtained by
accessing its internet server at United
States International Trade
Commission (USITC) at
https://www.usitc.gov. Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The
Commission has received a complaint
and a submission pursuant to § 210.8(b)
of the Commission’s Rules of Practice
and Procedure filed on behalf of Carl
Ziess SMT GmBH on July 20, 2018. The
complaint alleges violations of section
337 of the Tariff Act of 1930 (19 U.S.C.
1337) in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain lithography machines
and systems and components thereof (I).

The complaint names as
respondents: Nikon Corporation of
Japan; Nikon Research Corporation of
America of Belmont, CA; and Nikon
Precision Inc. of Belmont, CA. The
complainant requests that the
Commission issue a limited exclusion
order, cease and desist orders and
impose a bond upon respondents’
alleged infringing articles during the 60-
day Presidential review period pursuant
to 19 U.S.C. 1337(j).

Proposed respondents, other
interested parties, and members of the
public are invited to file comments,
not to exceed five (5) pages in length,
inclusive of attachments, on any public
interest issues raised by the complaint
or § 210.8(b) filing. Comments should
address whether issuance of the relief
specifically requested by the
complainant in this investigation would
affect the public health and welfare in the
United States, competitive
conditions in the United States
economy, the production of like or
directly competitive articles in the
United States, or United States
consumers.

In particular, the Commission is
interested in comments that:
(i) Explain how the articles
potentially subject to the requested
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the requested remedial
orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or third
party suppliers have the capacity to
replace the volume of articles
potentially subject to the requested
exclusion order and/or a cease and
desist order within a commercially
reasonable time; and
(v) explain how the requested
remedial orders would impact United
States consumers.

Written submissions on the public
interest must be filed no later than by
close of business, eight calendar days
days after the date of publication of this
notice in the Federal Register. There
will be further opportunities for
comment on the public interest after the
issuance of any final initial
determination in this investigation. Any
written submissions on other issues
should be filed no later than by close of
business nine calendar days after the
date of publication of this notice in the
Federal Register. Complainant may file
a reply to any written submission no
later than the date on which
complainant’s reply would be due
under § 210.8(c)(2) of the Commission’s
Rules of Practice and Procedure (19 CFR
210.8(c)(2)).

Persons filing written submissions
must file the original document
electronically on or before the
deadlines stated above and submit 8 true
copies to the Office of the Secretary by
noon the next day pursuant to § 210.4(f)
of the Commission’s Rules of Practice
and Procedure (19 CFR 210.4(f)).

Submissions should refer to the docket
number (“Docket No. 3328”) in a
prominent place on the cover page and/
or the first page. (See Handbook for
Electronic Filing Procedures, Electronic
The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: July 19, 2018.

John J. Martin,  
Assistant Administrator.

[FR Doc. 2018–15959 Filed 7–25–18; 8:45 am]  
BILLING CODE 7020–02–P

### DEPARTMENT OF JUSTICE

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices are listed in the table below. No comments or objections were submitted for these notices.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cedarburg Pharmaceuticals, Inc</td>
<td>83 FR 5275</td>
<td>February 6, 2018.</td>
</tr>
</tbody>
</table>

---


2 All contract personnel will sign appropriate nondisclosure agreements.